The Q4 2025 Multiple Sclerosis Market Highlights New Approval, Biosimilar Launch, And Pipeline Momentum 

TG Therapeutics launched a new patient-centered campaign for Briumvi in RMS, while also highlighting treatment uptake trends, brand differentiation, and access support.

Novartis activated several campaigns, shaping a prominent presence around Kesimpta in RMS messaging during the quarter. The materials also referenced patient support resources.

Novartis announced the approval of Rhapsido and introduced it as a newly available oral treatment option, generating early clinician awareness while promoting educational programming and patient access initiatives.

Sanofi outlined regulatory and clinical developments for tolebrutinib in progressive multiple sclerosis, reinforcing its differentiated scientific profile while also introducing a metaverse-based platform exploring the disease.

Sandoz announced the US launch of Tyruko, a multiple sclerosis biosimilar referencing Tysabri, establishing value-based positioning while highlighting Sandoz One Source support resources.